Open AccessPhotobiomodulation laser therapy in a Lenvatinib-related osteonecrosis of the jaw: A case report
Author(s) -
Luís S. Monteiro,
Catarina Vasconcelos,
José Júlio Pacheco,
Filomena Salazar
Publication year - 2021
Publication title -
journal of clinical and experimental dentistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.481
H-Index - 23
ISSN - 1989-5488
DOI - 10.4317/jced.58323
Subject(s) - medicine , osteonecrosis of the jaw , lenvatinib , adverse effect , dentistry , denosumab , surgery , bisphosphonate , thyroid , thyroid cancer , osteoporosis
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse drug reaction often presenting as a post-surgery complication that may interfere in the quality of the patient's life. In the last decade, additionally to bisphosphonates, other drugs have been associated with MRONJ including other antiresorptive, antiangiogenic or multitarget drugs such as levantinib. The data on MRONJ associated to lenvatinib is scarce with no guidelines for best management option. Our aim is to report a case of MRONJ associated with lenvatinib and the useful of a non-invasive management using local photobiomodulation (PBM) therapy with a 635nm diode laser.